Market Cap 59.81B
Revenue (ttm) 2.25B
Net Income (ttm) -278.16M
EPS (ttm) N/A
PE Ratio 1,965.00
Forward PE 239.87
Profit Margin -12.37%
Debt to Equity Ratio 0.00
Volume 603,581
Avg Vol 1,118,138
Day's Range N/A - N/A
Shares Out 132.11M
Stochastic %K 87%
Beta 0.30
Analysts Strong Sell
Price Target $500.33

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
HedgeAlerts
HedgeAlerts Nov. 14 at 6:27 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $460.00 Put · NOV 21, 2025 Exp Entry Price: $14.00 - $16.00 Exit Price Target: $30.88 Profit Margin: +93% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:47 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $450.00 Put · NOV 21, 2025 Exp Entry Price: $12.00 - $12.00 Exit Price Target: $17.16 Profit Margin: +43% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:06 AM
$ALNY is currently trading at $453.97, with an RSI of 46.28, indicating a neutral momentum. The price is below both the 30-day moving average (MA30) of $459.27 and the 50-day moving average (MA50) of $458.88, suggesting a bearish bias in the short term. The recent high of $495.55 and low of $417.00 over the past 60 days establishes a range that highlights potential volatility. Given the current metrics, a suggested entry point would be around $455, slightly above the last close, to capture potential upward movement if momentum shifts. A stop loss can be set at $445 to manage risk, while targets can be set at $465 (near MA30) and $475 (50% retracement of the recent high). This plan leverages the current price positioning relative to moving averages and the established high-low range for potential profit. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 13 at 9:18 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:12 AM
$ALNY is currently trading at $452.51, with an RSI of 45.13 indicating a neutral momentum, suggesting neither overbought nor oversold conditions. The price is below both the 30-day moving average (MA30) at $459.79 and the 50-day moving average (MA50) at $458.77, which indicates a bearish short-term trend. The recent high of $495.55 and low of $417.00 over the last 60 days further highlight a significant range, suggesting potential volatility. Given the current metrics, a directional bias leans slightly bearish. A suggested entry point could be around $450, with a stop loss set at $440 to manage risk. Target 1 can be set at $460, aiming for a retest of the MA30, while Target 2 can be positioned at $475, just below the recent high. This strategy allows for potential gains while managing downside risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:48 AM
$ALNY is currently trading at $452.51, with an RSI of 45.13 indicating a neutral momentum, suggesting neither overbought nor oversold conditions. The price is below both the 30-day moving average (MA30) at $459.79 and the 50-day moving average (MA50) at $458.77, which indicates a bearish short-term trend. The recent high of $495.55 and low of $417.00 over the last 60 days further highlight a significant range, suggesting potential volatility. Given the current metrics, a directional bias leans slightly bearish. A suggested entry point could be around $450, with a stop loss set at $440 to manage risk. Target 1 can be set at $460, aiming for a retest of the MA30, while Target 2 can be positioned at $475, just below the recent high. This strategy allows for potential gains while managing downside risk effectively. https://privateprofiteers.com
0 · Reply
IN0V8
IN0V8 Nov. 11 at 4:41 PM
$ALNY Wells Fargo raises PT to $479 from $395
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:22 PM
Wells Fargo has updated their rating for Alnylam Pharmaceuticals ( $ALNY ) to Equal-Weight with a price target of 479.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Nov. 9 at 11:16 AM
📈 $ALNY – Extending Rally in Final Stage 🔗 Full analysis https://elliottwave-forecast.com/stock-market/alnylam-alny-extending-rally-final-stage/ Alnylam Pharmaceuticals continues its bullish sequence, now likely in the final stage of wave ((5)). As long as price stays above the $148.88 pivot, the structure supports further upside before a larger correction unfolds. #ElliottWave #BiotechStocks #TechnicalAnalysis
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 1:19 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ALNY Contracts: $ALNY January 15, 2027 $450 Calls Scale in: $86.85- $106.15 Scale out: $337.75-$579.00 Profit Potential : 89% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Latest News on ALNY
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Oct 30, 2025, 2:39 PM EDT - 15 days ago

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

BNTX DHR GRAL ILMN IONS MRNA RGEN


Scenic Enters License and Research Agreement with Alnylam

Aug 26, 2025, 5:00 AM EDT - 2 months ago

Scenic Enters License and Research Agreement with Alnylam


Alnylam: Amvuttra Is Just Getting Started

Jul 31, 2025, 3:13 PM EDT - 3 months ago

Alnylam: Amvuttra Is Just Getting Started


Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Jul 1, 2025, 9:06 AM EDT - 4 months ago

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?


Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 12:04 PM EDT - 5 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief


Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025, 9:00 AM EDT - 6 months ago

Alnylam Issues 2024 Corporate Responsibility Report


HedgeAlerts
HedgeAlerts Nov. 14 at 6:27 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $460.00 Put · NOV 21, 2025 Exp Entry Price: $14.00 - $16.00 Exit Price Target: $30.88 Profit Margin: +93% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:47 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $450.00 Put · NOV 21, 2025 Exp Entry Price: $12.00 - $12.00 Exit Price Target: $17.16 Profit Margin: +43% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:06 AM
$ALNY is currently trading at $453.97, with an RSI of 46.28, indicating a neutral momentum. The price is below both the 30-day moving average (MA30) of $459.27 and the 50-day moving average (MA50) of $458.88, suggesting a bearish bias in the short term. The recent high of $495.55 and low of $417.00 over the past 60 days establishes a range that highlights potential volatility. Given the current metrics, a suggested entry point would be around $455, slightly above the last close, to capture potential upward movement if momentum shifts. A stop loss can be set at $445 to manage risk, while targets can be set at $465 (near MA30) and $475 (50% retracement of the recent high). This plan leverages the current price positioning relative to moving averages and the established high-low range for potential profit. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 13 at 9:18 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:12 AM
$ALNY is currently trading at $452.51, with an RSI of 45.13 indicating a neutral momentum, suggesting neither overbought nor oversold conditions. The price is below both the 30-day moving average (MA30) at $459.79 and the 50-day moving average (MA50) at $458.77, which indicates a bearish short-term trend. The recent high of $495.55 and low of $417.00 over the last 60 days further highlight a significant range, suggesting potential volatility. Given the current metrics, a directional bias leans slightly bearish. A suggested entry point could be around $450, with a stop loss set at $440 to manage risk. Target 1 can be set at $460, aiming for a retest of the MA30, while Target 2 can be positioned at $475, just below the recent high. This strategy allows for potential gains while managing downside risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:48 AM
$ALNY is currently trading at $452.51, with an RSI of 45.13 indicating a neutral momentum, suggesting neither overbought nor oversold conditions. The price is below both the 30-day moving average (MA30) at $459.79 and the 50-day moving average (MA50) at $458.77, which indicates a bearish short-term trend. The recent high of $495.55 and low of $417.00 over the last 60 days further highlight a significant range, suggesting potential volatility. Given the current metrics, a directional bias leans slightly bearish. A suggested entry point could be around $450, with a stop loss set at $440 to manage risk. Target 1 can be set at $460, aiming for a retest of the MA30, while Target 2 can be positioned at $475, just below the recent high. This strategy allows for potential gains while managing downside risk effectively. https://privateprofiteers.com
0 · Reply
IN0V8
IN0V8 Nov. 11 at 4:41 PM
$ALNY Wells Fargo raises PT to $479 from $395
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:22 PM
Wells Fargo has updated their rating for Alnylam Pharmaceuticals ( $ALNY ) to Equal-Weight with a price target of 479.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Nov. 9 at 11:16 AM
📈 $ALNY – Extending Rally in Final Stage 🔗 Full analysis https://elliottwave-forecast.com/stock-market/alnylam-alny-extending-rally-final-stage/ Alnylam Pharmaceuticals continues its bullish sequence, now likely in the final stage of wave ((5)). As long as price stays above the $148.88 pivot, the structure supports further upside before a larger correction unfolds. #ElliottWave #BiotechStocks #TechnicalAnalysis
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 1:19 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ALNY Contracts: $ALNY January 15, 2027 $450 Calls Scale in: $86.85- $106.15 Scale out: $337.75-$579.00 Profit Potential : 89% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
DocPharm
DocPharm Nov. 7 at 5:11 PM
$ABUS unless we get reversion of the OMERS payment this quarter or next, from $ALNY, 3 scenarios are going to play out in the near future: 1. New Share Offering or Debt Securities 2. Funding from codeveloper / partner (perhaps $ROIV) 3. Settlement from litigation Even with OMERs reversion, they will need to structure a new deal. Perhaps with someone like $CPRX or similar type company. They would need to front the money to make it back plus some upon milestones achieved
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Nov. 7 at 1:06 AM
$NTLA No respect for patients that sacrifice their lives for the greater good for human medicine advancement. You do realize that these patients are volunteers. They gain very little given thay there are 3 safe therapies already fda approved $BBIO $PFE $ALNY
0 · Reply
johnnygogogo
johnnygogogo Nov. 4 at 11:25 PM
$ALNY ok, joke of the day. If you have champagne at $400 and champagne at $450, what do you have at $425? A champagne split! Get it? @skeezbag
0 · Reply
johnnygogogo
johnnygogogo Nov. 4 at 7:17 PM
$ALNY 6 days ago, an AI-generated article from Simply Wall St stated: “ Alnylam Pharmaceuticals appears undervalued based on cash flows, trading at US$475.91, significantly below its estimated fair value of US$838.81.” And today in their “A Fresh Look at Alnylam Valuation” also AI-generated article, it reads “Result: Fair Value of $467.94 (UNDERVALUED)”. Simply Wall Street St can simply shut the fuck down because it’s all garbage. cc: @skeezbag
1 · Reply
prismmarketview
prismmarketview Nov. 4 at 6:10 PM
Royalty Pharma (NASDAQ: $RPRX) has acquired a 1% royalty interest in Alnylam’s (NASDAQ: $ALNY) AMVUTTRA™ for $310 million from Blackstone Life Sciences, covering global net sales from October 2025 through March 2035. AMVUTTRA is an FDA-approved RNAi drug for ATTR amyloidosis, with sales reaching $1.X billion in 2024 and projected to exceed $6 billion by 2028, offering Royalty Pharma immediate, long-term revenue from an established commercial asset while de-risking Alnylam’s cash flows. https://prismmarketview.com/royalty-pharma-acquires-310-m-royalty-stake-in-alnylam-pharmaceuticals-amvuttra-from-blackstone-life-sciences/
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 4 at 11:48 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $443.92 Contracts: $ALNY January 15, 2027 $450 Calls Scale in: $94.50- $115.50 Scale out: $147.00-$189.00 Can Easily Capture: 60% ROI Blended DTE: 438 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Investor6
Investor6 Nov. 4 at 10:29 AM
Jefferies latest coverages $ALNY with Buy recommendation, $DTM with $125 target price, $ET with Hold and tg $17 per share, PXED Buy with $46 tg (current sp $35.74) .
1 · Reply
johnnygogogo
johnnygogogo Nov. 3 at 2:53 PM
$ALNY was cooler before there was no p/e, now with a p/e of 1,397, they are not only the PLTR of bios but 2x PLTR p/e. Won’t matter, all about champagne and S&P 500 shoulder tap / secret handshake @skeezbag
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 3 at 12:38 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $456.04 Contracts: $ALNY January 15, 2027 $460 Calls Scale in: $77.37- $94.57 Scale out: $120.36-$154.75 Can Easily Capture: 60% ROI Blended DTE: 439 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 2 at 1:12 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALNY Current Share Price: $456.04 Contracts: $ALNY January 15, 2027 $460 Calls Scale in: $77.37- $94.57 Scale out: $120.36-$154.75 Can Easily Capture: 60% ROI Blended DTE: 440 Days | Join Elites here: https://liquidtheta.com
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 10:52 AM
Next major retail squeeze candidate right here $ALNY $ZTS $INSM $SYK ,,
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Nov. 2 at 8:42 AM
📈 Alnylam Pharmaceuticals – Rally in Final Stage 🔗 Read the full analysis https://elliottwave-forecast.com/stock-market/alnylam-alny-extending-rally-final-stage/ $ALNY is extending its bullish cycle from the April 2025 low, currently unfolding in wave (5) of a larger impulsive structure. The stock has already reached the minimum target zone of $494.95–$511.13, suggesting the rally is in its final stage before a potential correction. #ElliottWave #BiotechStocks #StockMarket #HealthcareSector
0 · Reply